Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.

The FDA on Fri­day is­sued two si­mul­ta­ne­ous cys­tic fi­bro­sis ap­provals for Ver­tex Phar­ma­ceu­ti­cals but in­clud­ed high-lev­el safe­ty warn­ings for both.

Separately, the FDA expanded the indication for Vertex's Trikafta on Friday to include cystic fibrosis patients with additional genetic variants. The FDA initially approved Trikafta in 2019 for ...

TRIKAFTA, a combination of elexacaftor, tezacaftor, and ivacaftor, is designed to enhance the function of the defective protein caused by cystic fibrosis transmembrane conductance regulator (CFTR) ...

Vertex Pharmaceuticals (VRTX) announced the U.S. Food and Drug Administration has approved the expanded use of Trikafta for the treatment of people with cystic fibrosis ages 2 and older who have ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...

Last but not least, we know that it is important to you what happens with the packaging when you are done with it, so we want to make sure that our packaging is easy to recycle—we obsess over every ...

The targets vary depending on the type of packaging used by operators (for instance, binding targets of 40% for transport and sales packaging and 10% for grouped packaging). According to the new rules ...

The European Council has formally adopted the Packaging and Packaging Waste Regulation, meaning it will now enter into force in EU law. As the final step in the ordinary legislative procedure, the ...